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The effects of alinidine on systemic and pulmonary haemodynamics and the ECG were studied in 8 patients early
after open heart surgery as a double-blind cross-over comparison between alinidine and placebo. Placebo had
no effect on any of the measured variables. Alinidine given as an i. v. bolus (10 mg) followed by an infusion
(10 mgh~') was associated with alinidine plasma levels of 172 ± 17 and 114 ± 13, respectively, (±SE, ngml~')
and decreased heart rate (-12%) and rate-pressure product (-14%) in all patients. While stroke volume index
tended to increase, there were no changes in arterial, pulmonary and atrial pressures, cardiac index, and
systemic and pulmonary vascular resistances. PR and QRS intervals of the ECG remained unaffected, and the
QTC interval transiently decreased. Alinidine appears to be a suitable drug for control of inappropriate sinus
tachycardia in patients with heart disease undergoing surgery.
Introduction
Heart rate (HR) is one of the major determinants
of myocardial oxygen balance'''. The control of HR is
an important part of the perioperative haemodyna-
mic management of patients with heart disease,
undergoing cardiac or non-cardiac surgery. Patients
with aortic or mitral stenosis and patients with coro-
nary artery disease are particularly vulnerable to the
adverse effects of sinus tachycardia occurring intra-
operatively of during the postoperative period'2'.
Beta-receptor blocking agents and parasympa-
thomimetic drugs effectively reduce the sinus node
rate, but their use in surgical patients may be limited
by untoward side-effects. Alinidine appears to be a
suitable drug for control on inappropriate sinus tac-
hycardia induced by surgery in patients with heart
disease.
However, there are no data on the efficacy and
safety of alinidine in this clinical setting. Therefore,
we investigated the effects of intravenous (i. v.) alini-
dine on systemic and pulmonary haemodynamics and
the electrocardiogram (ECG) in patients recovering
from open heart surgery.
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Methods
STUDY PATIENTS
Patients undergoing elective cardiac surgery (aor-
tocoronary bypass operation or valve replacement)
who gave written informed consent for the study,
which was approved by the institutional human stu-
dies committee, were eligible for the study.
The study was carried out in the early postopera-
tive hours. The patients entered the study when the
following criteria were fulfilled: (1) sinus rhythm with
a rate exceeding 90 beats min~', (2) functioning atrial
and ventricular pacing electrodes in situ, and (3)
stable postoperative course. The latter was defined
by stable haemodynamics, absence of arrhythmias,
urine output >0-5 ml kg"1, PaO2 > 120 mmHg,
PaCO2 < 45 mmHg, blood haemoglobin > 10 g
100 ml"1 rectal temperature >36-5°C and blood loss
from chest drains <1 ml kg"1 h"1. Patients who
received beta-blocking agents and/or calcium entry
blockers perioperatively, patients with reduced renal
function, and patients with atrioventricular conduc-
tion abnormalities were excluded.
Seven patients (6 male) after an uneventful aorto-
coronary bypass operation and one patient after
aortic valve replacement fulfilled the entry criteria
and were included in the study. Their age was 49 ± 3
SE, body weight 80 ± 14 kg, and height 171 ± lcm.
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The study was started on the average 6 h 50 min
(range 5 h 10 min-11 h 30 min) after the end of
operation. One patient was extubated prior to the
study, the remaining 7 patients were intubated and
ventilated throughout. They were sedated by diaze-
pam (2-5 mg h~ ') and morphine (2-5 mg h"1). Their
rectal temperature was 37-9 ± 0-9°C at the beginning
and 38-2 ± 0-8°C at the end of the study.
During the study 3 patients were receiving a con-
stant rate infusion of nitroglycerin (33, 80, and 80 ng
min"1, respectively) 1 patient was receiving nitro-
glycerin (120 u.g min"1), adrenaline (1-2 ug min"1)
and lidocaine (2 mg min"1). All eight patients com-
pleted the study and there were no drop outs.
HAEMODYNAMIC MEASUREMENTS
Arterial pressure (AP) was measured by means of
a 20 gTeflon® cannula inserted into the radial artery.
Right atrial and pulmonary artery pressures (RAP,
PAP) were measured by a balloon directed triple
lumen Swan-Ganz catheter inserted through the
right jugular internal vein into the pulmonary artery.
Left atrial pressure (LAP) was measured by a cath-
eter inserted into the left atrium through the right
upper pulmonary vein following pericardiotomy. All
catheters were connected to pressure transducers
(COBE 41-500, COBE Laboratories, Lakewood,
CO) with 150 cm stiff polyethylene tubing. The zero
level was adjusted at mid-chest level. The transduc-
ers were calibrated with a mercury manometer. A
multiple channel recorder (Hellige. Freiburg i. Br.,
F.R.G.) was used for recording the pressures along
with (ECG). Mean pressures (APm, PAPm, RAP,
LAP) were obtained by electronic integration.
Edwards Lab Cardiac Output Computer (Santa
Ana, CA. model 93-132-5F) was used for cardiac
output (CO) measurements. At end-expiration. 10
ml of iced 5% dextrose solution were injected into
the proximal port of the triple lumen thermodilution
catheter. During the first 10 min after each bolus
injection of the study drug CO was determined in
duplicate, whereas triplicate measurements were
performed thereafter.
Cardiac index (CI), stroke volume index (SVI),
systemic and pulmonary vascular resistances (SVR.
PVR), left ventricular stroke work index (LVSWI)
and right ventricular stroke work index (RVSWI)
were calculated according to standard formulae'3'.
Heart rate (HR) was derived from the ECG. Rate-
pressure product was calculated as the product of
heart rate and peak arterial systolic pressure.
ELECTROCARDIOGRAM
Leads II and V5 of the ECG were recorded simul-
taneously with the pressures (chart speed 50 mm s"1)
and analyzed for RR, PR, QRS and QT intervals.
Each value represents the mean of 5 heart cycles
recorded at end-expiration. The rate corrected QTC
interval was calculated accordingly to the Bazett
formula : QTC = QT/VRR. In addition both ECG
leads were analyzed for significant (5=1 mm) shifts of
the ST segment and changes in the configuration of
the T waves. A standard 12-lead ECG was recorded
before and after the study.
ALINIDINE PLASMA LEVELS
Blood samples for alinidine concentration were
taken from the indwelling radial artery cannula at the
end of both control periods, 2 min after the end of
each bolus injection and at the end of each infusion
period. The blood samples were immediately hepari-
nized using 0025 ml Heparin NOVO®.
Plasma samples were prepared by centrifugation
(10 min at 3000 x g) and kept frozen (-20°C) until
analyzed. The concentration of alinidine in the
plasma samples were determined by a radioimmu-
noassay method'4'.
EXPERIMENTAL PROTOCOL
The study design was a randomized double-blind
cross over comparison between alinidine and placebo
(Fig. 1).
The first control period of 1 hour served to assess
the stability of the haemodynamics and the persis-
tence of the entry criteria. Then 10 ml of saline
containing either 10 mg of alinidine or placebo were
injected into a separate central venous catheter over
30 s and an alinidine (10 mg h"1) or placebo infusion
was started. The infusion was terminated 60 minutes
after the end of the bolus and 60 minutes were
allowed for wash out. Then the second bolus dose
was injected and the second infusion of alinidine/
placebo was started.
Plocebo Placebo
Alinidme Wosh-out Anriid;ne
Figure I Diagram of the cross-over design of the present
study.
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Haemodynamic and ECG measurements were used to deliver the study drug at a constant infusion
performed at the end of each control period and 2, 4, rate of 1-7 ml min"1.
6, 8, 10. 20, 30 and 60 min after each bolus dose.
The test drugs were provided in ampuls containing Results
10 mg in 2 ml of solvent. Immediately before each HAEMODYNAMIC (TABLES I AND 2)
experiment the bolus injection and the infusion were The control haemodynamics were characterized by
prepared by adding 0-9% NaCl solution to the con- low SVR and increased HR and CI. There were no
tent of the original ampul to yield a final concentra- differences in control values between the alinidine
tion of 1 mg ml"1 and 01 mg ml"1 for the bolus and placebo phase.
injection and the infusion, respectively. An infusion Placebo had no effects on any of the measured
pump (Diginfusa, Schoch, Zurich, Switzerland) was haemodynamic variables. Alinidine in contrast
Table 1 The effects of alinidinel placebo on systemic haemodynamics
Variable
HR (min ')
APm (mmHg)
LAP (mmHg)
SVI (ml rrr2)
CI (1 min ' m ' - )
SVR (dyn s cm s)
LVSWI (g m m 2)
HRAP S ) , (mmHg min ' 10
A
P
A
P
A
P
A
P
A
P
A
P
A
P
3) A
P
C
103 ± 5
100 ± 2
72 ± 2
73 ± 4
10 ± 1
11 ± 1
35 + 3
35 ± 2
3-6 ± 0-3
3-5 + 0-3
757 ± 91
822 ± 109
29 ± 2
29 + 2
12-5 ± 0-8
11-8 ± 0-4
10 min after bolus
91 ± 3t1
101 ±3 I "
71 ± 2
72 + 4
11 ± 1
11 ± 1
37 ± 2
34 ± 3
3-4 ± 0-3
3-4 ± 0-3
786 ± 77
817 ± 109
30 ± 2
28 + 2
10-8 ± O-6+i
11-8 ± 0-4 I *
The values are means ± SE. C = control. A = alinidine.
P = placebo. HR = heart rate. AP sys = systolic arterial pressure.
APm = mean arterial pressure. LAP = mean left atrial pressure.
SVI = stroke volume index, CI = cardiac index, SVR = systemic
vascular resistance, LVSWI = left ventricular stroke work index.
H R - A P , , ! = ra te -p ressure product , 1 mmHg = 0 1 3 3 kPa.
* = P < 005 compared to placebo, " = P < 001 compared to
placebo, t = P<00] compared to control, % = P < 005 compared to
control.
Table 2 The effects of alinidinel placebo on pulmonary haemodyna-
mics and right ventricular pump function
Variable
RAP (mmHg)
PAPm (mmHg)
PVR (dyn s c m 5 )
RVSWI (g m m~2)
A
P
A
P
A
P
A
P
C
10 ± 1
10 ± 1
19 ± 2
19 ± 1
107 ± 9
102 ± 15
5 ± 1
5 ± 1
10 min after bolus
10 ± 1
10 ± 1
19 ± 2
19 ± 1
102 ± 11
106 ± 6
4 ± 1
4 ± 1
RAP = mean right atrial pressure, PAP = mean pulmonary artery
pressure, PVR = pulmonary vascular resistance, RVSWI = right
ventricular stroke work index. The values are means ± SE, C = con-
trol, A = alinidine, P = placebo.
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caused a consistent decrease in HR in all patients
(Fig. 2). The effect was already present 2 min after the
bolus and was maintained during alinidine infusion
(-9% to -12%). There was a significant correlation
between the decrease in HR (AHR) and the control
value of HR (r = -0-72, P < 005) (Fig. 3). The
decrease in HR was associated with a slight increase
in SVI. At 2 min and 20 min after the bolus the
changes in SVI were significant, at the other
measurements, however, only an upward trend
(P < 0-07-0-1) was present. The other haemodyna-
mic variables remained uneffected.
The rate-pressure product decreased by 11% and
14% 2 and 60 minutes after the bolus, respectively
(Fig. 4).
ELECTROCARDIOGRAPHIC INTERVALS (TABLE 3)
Neither placebo nor alinidine had any effects on
PR and QRS intervals. QTinterval, however, tended
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Figure 2 Effects of placebo and alinidine on heart rate.
it = P < 0-01 compared to control and placebo.
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Figure 3 Relation between control heart rate and change
in heart rate (A) after 1 h infusion of (10 mgh"1) alinidine.
There is a slight correlation between both variables
(r = -0-72).
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Figure 4 Effects of placebo and alinidine on rate-pressure
product (•& = P < 005 compared to placebo).
Table 3 The effects of alinidinelplacebo on ECC intervals
Variable
PR (ms)
QRS (ms)
QT (ms)
QTC (ms)
A
P
A
P
A
P
A
P
C
164 ± 7
163 ± 7
83 ± 7
81 ± 7
324 ± 6
325 ± 5
424 ± 12
420 ± 9
10 min after bolus
164 ± 7
164 ± 7
82 ± 6
84 ± 6
333 ± 3
330 ± 3
411 + lOt
428 ± 8
Values are means ± SE. A = alinidine, P = placebo, C = control.
X = P < 005 compared to control.
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Table 4 Plasma levels of alinidine
Time after bolus
2 min 60 min 120 min 180 min
(wash-out)
(N = 7) (A' = 8) (N = 4) (;V = 4)
Plasma level (ng ml ~ ' ) 172 ± 17 114 ± 14 40 ± 8 32 ± 9
Values are means ± SE.
to increase during the first 6 min after the alinidine
bolus (P < 0-055). The rate corrected QTC interval
decreased 2, 4 and 10 min after alinidine. No changes
in the ST segments were detected and the T-wave
morphology also did not change.
ALINIDINE PLASMA LEVELS (TABLE 4)
Alinidine plasma level 2 min after the bolus was
171 ± 17 ngmP1 and decreased to 114 ± 13ngml~'
at the end of the alinidine infusion. At 1 h and 2 h
after the cessation of the infusion, alinidine was still
present in plasma.
Alinidine plasma levels correlated significantly
with the maximal decrease in HR (AHR) both dur-
ing the first 10 min after injection (r = —0-76,
P < 001) and at the end of the alinidine infusion
(r = -0-59, P < 005) (Fig. 5). The decrease in
plasma level during the following wash-out corre-
sponds to a plasma elimination half-time of 5 h.
There were no side-effects related to alinidine
administration. All patients had an uneventful post-
operative recovery.
r = -0-59 {P <O-O5)
- 2 0 u. J
50 100 150 200
Alinidine plosmo level (nq ml"')
Figure 5 Relation between change in heart rate (A) and
alinidine plasma levels after infusion of alinidine. There is a
slight correlation between both variables (r = -0-59).
Discussion
In this study alinidine administered to patients
recovering from open heart surgery consistently
decreased HR without causing any adverse haemo-
dynamic effects. Placebo, in contrast, had no effects
on the haemodynamics. This documents the haemo-
dynamic stability of our patients during the experi-
ment. According to the randomization order, half of
the patients were given placebo following an incom-
plete wash-out of alinidine. The presence of subclini-
cal alinidine levels in these patients had no apparent
effect on their response to placebo.
In the early postoperative period the haemodyna-
mic pattern changes with time and, consequently, the
effects of alinidine might have been modified by the
actual haemodynamic function at the time of its
administration.
Prior to administration of alinidine our patients
exhibited an uniform haemodynamic pattern of peri-
pheral vasodilation, characterized by low SVR,
normal atrial pressures, and increased Cl associated
with a mild sinus tachycardia. Heart failure can,
therefore, be excluded as a cause of the tachycardia.
Moreover, there were no signs of hypovolaemia,
anaemia, cardiac tamponade, or perioperative myo-
cardial infarction, all conditions which may also be
responsible for tachycardia. However, all patients
had an increased body temperature.
Thus, the increased HR in our patients can be best
explained by the combined effects of fever, and high
postoperative sympathetic tone with increased levels
of circulating catecholamines'5'.
The fact that the decrease in HR after alinidine was
not accompanied by any deterioration in the cardiac
pump function confirms that the tachycardia was not
essential for the maintenance of an adequate flow.
On the other hand, the question arises whether in
these patients the reduction in HR due to alinidine
was beneficial.
When in a similar group of patients early after
aortocoronary bypass operations the HR was
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increased from 87 to 112 beats min ' by atrial pacing,
signs of anaerobic metabolism and decrease in myo-
cardial compliance suggestive of myocardial ischemia
occurred'6'. In patients after cardiac valve replace-
ment atrial pacing at 128 beats min"1 similarly de-
teriorated the myocardial oxygen balance'7'. Conse-
quently, tachycardia appears to have an unfavorable
effect in the early postoperative period and may
interfere with the recovery of the ventricular func-
tion. This may be particularly important in patients
with incomplete revascularization, perioperative
myocardial infarction and left ventricular hyper-
trophy.
Experimental studies demonstrated beneficial
effects of slowing the HR in the presence of reduced
coronary reserve'8'. In animal models with severe
coronary artery stenosis alinidine, in a dose which
decreased HR by 25%, caused a marked redistri-
bution of coronary flow in favor of the subendocard-
ium and improved regional myocardial function in
the poststenotic area'910'. Our patients, however,
were successfully revascularized and no one had a
manifest myocardial ischemia. The question of any
benefit from alinidine therapy cannot be answered
without special measurements of regional myocardial
function and metabolism.
Our findings confirm the previous reports on the
negative chronotropic effects of i.v. alinidine, which
was found to decrease H R both at rest and exercise''''
and to reduce tachycardia due to surgery'12', acute
myocardial infarction'13', and dobutamine and nitro-
prusside infusion'1415'. The dose used in our study
(approximately 0-125 mg kg"1) was considerably
smaller than the doses of 0-3-0-6 mg kg"1 used by
other authors. The negative chronotropic effect of
alinidine elicited by the bolus injection could be
maintained by the subsequent infusion in a dose as
low as 2 /xg kg"1 min"1. The use of a lower dose can
explain both the lack of adverse haemodynamic
effects and the rather moderate bradycardic effect
found in this study.
Although alinidine decreased HR, it had no effect
on atrioventicular and intraventricular conduction.
This has been previously reported even after con-
siderably higher doses'16' and is of major importance
in patients early after cardie surgery, who may have
conduction abnormalities. The slight and transient
decrease in QTC interval appears to result primarily
from the slowing of the HR and may reflect a
decrease in dispersion of repolarization in ventricular
myocardium'17'. Such an effect would increase the
electrical stability of the heart.
In conclusion the present study clearly reveals that
i.v. alinidine is effective in reducing postoperative
tachycardia without exhibiting any adverse effects on
global pump function of the heart. Because of its
specific negative chronotropic action alinidine may
be preferable to other bradycardic agents for control
of inappropriate sinus tachycardia in patients with
heart disease undergoing surgery. Further studies,
however, will be necessary to determine the optimum
dose, mode of administration, and the interactions
with other drugs and anethesthics used in the peri-
operative setting.
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